B in relapsed or refractory multiple myeloma Fda granted accelerated approval of elrexfio for the treatment of adult patients with relapsed or refractory multiple myeloma (rrmm) who have received at least four prior lines of therapy, including a. T dosing of elranatamab in patients with relapsed or r mab in the majestec1 study of patients with relapsed/re tory multiple myeloma
Total cost of care and cost per month of pfs were also assessed In august 2023, the u.s An estimated 14 (commercial) and 60 (medicare) rrmm patients per year would be eligible for treatment
For patients who have relapsed following two to four prior treatments
